FIRST REAL-WORLD HEMATOLOGIC ADVERSE EVENTS EXPERIENCE WITH NIRAPARIB IN ADVANCED OVARIAN CANCER

被引：0
|
作者：
Wang, Junjian [1 ]
Zhu, Jianqing [1 ]
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-ESGO.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
418
引用
收藏
页码：A79 / A80
页数：2
相关论文
共 50 条
  • [41] REAL-WORLD EXPERIENCE AND COMMON ADVERSE EVENTS WHEN USING COMBINATION LENVATINIB AND PEMBROLIZUMAB FOR THE TREATMENT OF RECURRENT UTERINE CANCER
    Zammarrelli, William
    Espino, Kevin
    Yeoshoua, Effi
    Ehmann, Sarah
    Rubinstein, Maria
    Green, Angela
    Makker, Vicky
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A111 - A112
  • [42] Patient characteristics, treatment patterns and real-world effectiveness of niraparib in France: an ESME retrospective study in recurrent ovarian cancer patients treated with niraparib maintenance
    Gladieff, Laurence
    Macouillard, Pauline
    Toussaint, Philippe
    El-Mouaddin, Nadia
    Jacquemin, Virginie
    Fages, Anne
    Nachbaur, Gaelle
    Gourgou, Sophie
    Pomel, Christophe
    Colombo, Pierre-Emmanuel
    Bosquet, Lise
    Rodrigues, Manuel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A307 - A308
  • [43] Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
    Arnold Lee
    Targeted Oncology, 2021, 16 : 839 - 845
  • [44] Real-world evidence in the treatment of ovarian cancer
    Eisenhauer, E. A.
    ANNALS OF ONCOLOGY, 2017, 28 : 61 - 65
  • [45] Editorial: Real-world data and real-world evidence in hematologic malignancies
    Malagola, Michele
    Ohgami, Robert
    Greco, Raffaella
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [46] Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
    Joly, Florence
    Bazan, Fernando
    Garbay, Delphine
    Ouldbey, Yaelle
    Follana, Philippe
    Champeaux-Orange, Elise
    Legouffe, Eric
    Brachet, Pierre-Emmanuel
    Spaeth, Dominique
    Combe, Pierre
    Hardy-Bessard, Anne-Claire
    Selle, Frederic
    Grenier, Julien
    Lebreton, Coriolan
    Derbel, Olfa
    Bonnet, Elise
    Fournel, Pierre
    Diez, Yolanda Fernandez
    Delecroix, Valerie
    Emambux, Sheik
    Alexandre, Jerome
    Grellety, Thomas
    Mille, Dominique
    Orfeuvre, Hubert
    Favier, Catherine
    Le Roux, Delphine
    Mouret-Reynier, Marie-Ange
    Quesada, Stanislas
    Kurtz, Jean-Emmanuel
    JNCI CANCER SPECTRUM, 2025, 9 (01)
  • [47] Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
    Lee, Arnold
    TARGETED ONCOLOGY, 2021, 16 (06) : 839 - 845
  • [48] Niraparib maintenance therapy in advanced ovarian cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (03) : 237 - 237
  • [49] Predictive Modeling of Drug-Related Adverse Events with Real-World Data: A Case Study of Linezolid Hematologic Outcomes
    Patel, Anu
    Doernberg, Sarah B.
    Zack, Travis
    Butte, Atul J.
    Radtke, Kendra K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (04) : 847 - 859
  • [50] Cardiovascular and non-cardiovascular adverse events in patients with hematologic malignacies treated with BTK inhibitors: a real-world analysis
    Nunes, R. Belo
    Baiocchi, O. C. C.
    Marques, M. O.
    Bachour, P.
    Avezum, A.
    EUROPEAN HEART JOURNAL, 2024, 45
12345